The Potential Role of Glutamate Transporters in the Pathogenesis of Normal Tension Glaucoma
Overview
Authors
Affiliations
Glaucoma, a progressive optic neuropathy due to retinal ganglion cell (RGC) degeneration, is one of the leading causes of irreversible blindness. Although glaucoma is often associated with elevated intraocular pressure (IOP), IOP elevation is not detected in a significant subset of glaucomas, such as normal tension glaucoma (NTG). Moreover, in some glaucoma patients, significant IOP reduction does not prevent progression of the disease. Thus, understanding IOP-independent mechanisms of RGC loss is important. Here, we show that mice deficient in the glutamate transporters GLAST or EAAC1 demonstrate spontaneous RGC and optic nerve degeneration without elevated IOP. In GLAST-deficient mice, the glutathione level in Müller glia was decreased; administration of glutamate receptor blocker prevented RGC loss. In EAAC1-deficient mice, RGCs were more vulnerable to oxidative stress. These findings suggest that glutamate transporters are necessary both to prevent excitotoxic retinal damage and to synthesize glutathione, a major cellular antioxidant and tripeptide of glutamate, cysteine, and glycine. We believe these mice are the first animal models of NTG that offer a powerful system for investigating mechanisms of neurodegeneration in NTG and developing therapies directed at IOP-independent mechanisms of RGC loss.
Should poor sleep be added to the list of risk factors for normal-tension glaucoma in the future?.
Wostyn P, Nedergaard M Eye (Lond). 2025; .
PMID: 40044838 DOI: 10.1038/s41433-025-03748-8.
Optineurin-facilitated axonal mitochondria delivery promotes neuroprotection and axon regeneration.
Liu D, Webber H, Bian F, Xu Y, Prakash M, Feng X Nat Commun. 2025; 16(1):1789.
PMID: 39979261 PMC: 11842812. DOI: 10.1038/s41467-025-57135-8.
Yang Y, Zhou H, Hong Z Front Nutr. 2024; 11:1461748.
PMID: 39512517 PMC: 11541052. DOI: 10.3389/fnut.2024.1461748.
Glial cells as a promising therapeutic target of glaucoma: beyond the IOP.
Shinozaki Y, Namekata K, Guo X, Harada T Front Ophthalmol (Lausanne). 2024; 3:1310226.
PMID: 38983026 PMC: 11182302. DOI: 10.3389/fopht.2023.1310226.
Monogenic gene therapy for glaucoma and optic nerve injury.
Harada C, Guo X, Harada T Neural Regen Res. 2024; 20(3):815-816.
PMID: 38886952 PMC: 11433919. DOI: 10.4103/NRR.NRR-D-24-00133.